

# DiagnosTear

## **DiagnosTear Technologies Inc. Commenced Trading on the Canadian Securities Exchange**

**December 10, 2024 – Vancouver, BC – DiagnosTear Technologies Inc. ("DiagnosTear" or the "Company")** is pleased to announce that the Company's common shares have commenced trading on The Canadian Securities Exchange ("CSE" or "the Exchange") on Monday, December 9, 2024 under the symbol "DTR".

DiagnosTear is focused on the development and commercialization of disruptive diagnostic solutions for better management of eye diseases. The Company's TeaRx™ technology is a diagnostic platform intended for rapid, point-of-care testing of ophthalmic pathologies through tear fluid. The Company is currently developing products for the diagnosis of Dry Eye Disease and Red Eye causes.

"We are thrilled with the commencement of trading on the CSE. Building on our unique expertise in multi-parametric analysis of the tear fluid, our efforts are focused on becoming a global leader in the development and commercialization of point of care diagnostic tools for ocular diseases like dry eye and red eye", said Yaacov Michlin, DiagnosTear's Chairman of the Board. Dr. Shimon Gross, DiagnosTear's CEO also commented: "Our solutions are non invasive, simple to perform and to interpret, and will allow healthcare providers to deliver a higher standard of care that target the underlying cause of the disease and provide personalized treatment options. We have received approval to market in Europe our dry eye product and will commence commercialization during 2025 and hope to approach the FDA in 2025 with our red eye product; while continuing to work with leading research institutions to improve the care our technology provides to patients."

### **About DiagnosTear**

DiagnosTear is a leading ophthalmic company developing and commercializing disruptive diagnostic solutions for better management of eye diseases. DiagnosTear's TeaRx™ technology is a diagnostic platform intended for rapid, Point-of-Care Testing (POCT) of ophthalmic pathologies through multi-parameter analysis of non-invasively collected tear fluid. The first CE-IVD, and Israeli MoH-approved test based on the TeaRx™ platform is intended for diagnosis of Dry Eye Syndrome (DES TeaRx™ Dry Eye). This product is not FDA-cleared yet. Beyond DES, DiagnosTear is developing innovative tests based on the TeaRx™ platform for additional ophthalmic indications. Among others, DiagnosTear's pipeline includes TeaRx™ Red Eye: The first test of its kind for differential assessment of adenoviral conjunctivitis, Herpetic Keratitis and Allergic conjunctivitis. For additional information about DiagnosTear, please visit <https://bio-light.co.il/diagnos-tear/>

Dr. Shimon Gross  
Chief Executive Officer  
DiagnosTear Technologies Inc.  
Email: [shimon@diagnostear.com](mailto:shimon@diagnostear.com)  
Tel: +972-523408550

## **Forward-Looking Statements**

*Certain statements and information herein, including all statements that are not historical facts, contain forward-looking statements and forward-looking information within the meaning of applicable securities laws. Such forward-looking statements or information include but are not limited to statements or information with respect to: discussions with the Food and Drug Administration in the United States, efforts to improve the test care kits and collaboration with research institutions. Often, but not always, forward-looking statements or information can be identified by the use of words such as "estimate", "project", "belief", "anticipate", "intend", "expect", "plan", "predict", "may" or "should" and the negative of these words or such variations thereon or comparable terminology are intended to identify forward-looking statements and information. With respect to forward-looking statements and information contained herein, DiagnosTear has made numerous assumptions including among other things, assumptions about general business and economic conditions. The foregoing list of assumptions is not exhaustive.*

*Although management of DiagnosTear believes that the assumptions made and the expectations represented by such statements or information are reasonable, there can be no assurance that forward-looking statements or information herein will prove to be accurate. Forward-looking statements and information by their nature are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements or information. These factors include, but are not limited to, those factors discussed under the heading "Risk Factors" in the non-offering prospectus of DiagnosTear dated November 14, 2024. DiagnosTear does not undertake to update any forward-looking information, except in accordance with applicable securities laws.*